Information Provided By: 
Fly News Breaks for January 18, 2018
EXAS
Jan 18, 2018 | 09:24 EDT
Craig-Hallum analyst Kevin Ellich is a buyer of Exact Sciences following selloff as he thinks the abstract highlighting CTC blood test results for the CellMax CMx platform that's being presented this weekend at the 2018 ASCO Gastrointestinal Cancers Symposium is noise. While the sensitivity and specificity were good, the study was at one center and had a disproportionate number of diseased patients in a potentially high-risk population, he contends. The analyst reiterates a Buy rating and $61 price target on the shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
